Physician profile
Roberto Lopez
NPI 1144279373
$3,941.46
in general payments reported to CMS, 2019-2025
31 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $318 · 2022: $337 · 2023: $532 · 2024: $442 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $531.36 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $303.19 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $237.13 | 2019-2022 | |
| Amgen INC. | $184.10 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $181.11 | 2019-2025 | |
| Exact Sciences Corporation | $174.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $173.28 | 2019-2020 | |
| Abbvie INC. | $171.06 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.57 | 2019-2023 | |
| Corcept Therapeutics | $117.50 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $104.41 | 2019-2022 | |
| Abbott Laboratories | $95.23 | 2019-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $93.31 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boston Scientific Corporation | $89.10 | 2019-2024 | Watchman Flx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $87.73 | 2019-2020 | |
| Astellas Pharma US INC | $83.79 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.67 | 2019 | |
| Allergan, INC. | $45.78 | 2019-2020 | |
| Si-Bone, INC. | $41.37 | 2024 | |
| Dynavax Technologies Corporation | $37.78 | 2023-2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $28.94 | 2019 | |
| Optinose US, INC. | $28.40 | 2024 | |
| Inari Medical, INC. | $27.99 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Nalpropion Pharmaceuticals LLC | $24.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.16 | 2019 | |
| Esperion Therapeutics, INC. | $18.04 | 2024 | Nexletol |
| Dexcom, INC. | $12.71 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.